Innovation Management and Technology Transfer
Transfer strategy
The transfer of research results into medical and pharmaceutical applications plays a central role at the HZI. In addition to scientific exchange, the aim is to pave the way for the transfer of technology and knowledge into practical - possibly commercial - application. The Centre is therefore committed to sustainable technology transfer to third parties, including small and medium-sized enterprises and industry. The HZI's national and international position in research and development is to be sustainably strengthened in the coming years through an attractive transfer portfolio including a broad spectrum of innovative active agents, novel diagnostic procedures and their transfer into clinical application as well as innovative digital health technologies.
The translational research approach will make the HZI an even more attractive partner for companies as well as open up new career opportunities for young talents, e.g. in the context of spin-offs. The HZI will fulfil its responsibility even better in the future through the targeted transfer of knowledge to society and politics.
Find out more about the Helmholtz Association's transfer strategy here.
The H3 Health Hub - A Helmholtz Transfer Academy - is a joint program of the six Helmholtz Health centers. It enables researchers, employees and aspiring entrepreneurs to successfully transfer results from lab into business. H3 provides a platform for community, learning, events and collaborative projects in this field. The partners from the regional life science ecosystems are integrated closely throughout the process.
The team includes experts from technology transfer, innovation management and human resources development from all centers to cover the entire development process of aspiring entrepreneurs. In addition, it is supported by an advisory board of experts who provide with strategic support.
IP Office
The outstanding research carried out by the scientists at the HZI not only serves to gain knowledge, but also aims to produce new pharmaceuticals, diagnostics, digital tools, preventive measures and treatment methods. For this to succeed, scientific inventions resulting from HZI research must be protected by intellectual property rights and thus made usable for transfer to clinical application. Securing intellectual property rights is the task of the IP Office. Together with its partners, specialized patent attorneys and the knowledge and technology company Ascenion GmbH, the IP Office works to convert extraordinary research results into intellectual property rights and thus make them accessible to the general public. In this way, the visibility and global leadership role of the HZI in infection research is strengthened and secured through a strong and constantly growing patent portfolio.
